Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios.The worldwide telehealth market was $122.2 billion in 2023 and is anticipated to rise 28.4% annually from 2024 to 2032. Another forecast predicts $368.7 billion in market growth at 40% per year from 2023 to 2028.North America led the market in 2023 owing to higher healthcare IT spending, more interne ...

SALT LAKE CITY, June 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has successfully completed its acquisition of Carevive Systems ("Carevive"), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer.Oncology providers and life science researchers use Carevive's flagship platform and/or C ...

SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jason Alger, Chief Financial Officer, and Jack Knight, Vice President of Investor Relations, will participate in the following upcoming investor conferences: The Stifel Cross Sector Insight Conference, being held in Boston, including a fireside chat on Tuesday, June 4, 2024, at 9:45am ET. T ...

Investors might want to bet on Health Catalyst (HCAT) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.The upward trend in estimate revisions for this provider of data analytics for the health care industry reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical re ...

Shares of Health Catalyst (HCAT) have gained 11.6% over the past four weeks to close the last trading session at $6.73, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.79 indicates a potential upside of 75.2%.The average comprises 14 short-term price targets ranging from a low of $8 to a high of $16, with a standard deviation of $2.72. While the lowest estimate indicates an ...

SALT LAKE CITY, May 21, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of Health Catalyst Ignite®, a next-generation healthcare data and analytics ecosystem that combines best-in-class technologies, healthcare-specific data models, self-service tools, and industry expertise in one modern environment.Today's health systems face significant challenges in naviga ...

财务数据和关键指标变化 - 第一季度总收入为7.47亿美元,略高于指引中值 [13] - 调整后EBITDA为340万美元,也超过了指引中值 [13] - 技术业务收入为4.7亿美元,与去年同期基本持平 [42] - 专业服务收入为2.78亿美元,同比增长4% [42] - 总调整毛利率为51%,同比下降约70个基点 [43] - 技术业务调整毛利率为68%,同比下降约140个基点 [43] - 专业服务调整毛利率为22%,同比提升约190个基点 [44] 各条业务线数据和关键指标变化 - 技术业务收入保持平稳,专业服务收入同比增长4% [42] - 专业服务毛利率同比提升,主要得益于去年四季度的裁员 [44][45] 各个市场数据和关键指标变化 - 沙特德国健康集团在阿联酋的医院实施了公司的数据分析平台和成本管理等解决方案,这是公司在中东地区的一次重要拓展 [36][37] 公司战略和发展方向及行业竞争 - 公司推出了新一代数据分析平台"Health Catalyst Ignite",未来新客户部署将使用该平台,现有客户也将在未来2-3年内逐步迁移 [31][32] - 公司在M&A方面保持谨慎,未来可能会考虑一些技术层面的小型收购 [38][39] - 公司看好未来行业环境的改善,预计2024年订单增长将重拾双位数增长 [33][34][35] 管理层对经营环境和未来前景的评论 - 管理层对公司在2022-2023年度经历的行业困难表示理解,并认为公司已经度过了最困难的时期 [100][101][102][103] - 管理层对公司未来的技术发展和业务拓展前景表示乐观,认为公司有望实现持续的双位数增长 [108][109][110][111] 问答环节重要的提问和回答 问题1 **Jared Haase 提问** 询问公司未来M&A的重点领域和财务标准 [64][65][66][67] **Daniel Burton 和 Jason Alger 回答** 公司未来M&A的重点将集中在措施和注册等领域,主要考虑技术驱动型的小型收购,同时也会关注收购对公司利润的影响 [66][67][70] 问题2 **Elizabeth Anderson 提问** 询问专业服务毛利率改善的原因,以及未来趋势 [73][74][75] **Daniel Burton 和 Jason Alger 回答** 专业服务毛利率改善主要得益于去年四季度的裁员,以及技术驱动型服务业务的占比提升,未来预计会有一定压力但仍将维持在较高水平 [73][74][75] 问题3 **Anna Kruszenski 提问** 询问Change Healthcare事件对公司业务的影响,以及沙特德国健康集团业务在公司整体中的占比 [85][86][91][92] **Daniel Burton 回答** Change Healthcare事件对公司业务影响有限,公司与沙特德国健康集团的业务合作属于国际市场,占公司整体收入比重较小 [86][91][92]

Health Catalyst (HCAT) reported $74.72 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 1.2%. EPS of $0.05 for the same period compares to $0.05 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $74.81 million, representing a surprise of -0.11%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being $0.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...

Health Catalyst (HCAT) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this provider of data analytics for the health care industry would post a loss of $0.01 per share when it actually produced earnings of $0.02, delivering a surprise of 30 ...

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38993 HEALTH CATALYST, INC. (Exact name of registrant as specified in its chart ...